These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 38622462

  • 1. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
    Matsumura T, Sonoda M, Okimoto K, Dao HV, Takahashi S, Akizue N, Horio R, Goto C, Kurosugi A, Kaneko T, Ohta Y, Taida T, Kikuchi A, Fujie M, Kato J, Kato N.
    Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
    [Abstract] [Full Text] [Related]

  • 2. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
    Hamada S, Ihara E, Ikeda H, Muta K, Ogino H, Chinen T, Tanaka Y, Ogawa Y.
    Digestion; 2021 Jun; 102(2):197-204. PubMed ID: 31578027
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J, Hosaka H, Kuribayashi S, Moriyasu S, Hisada Y, Okubo H, Watanabe K, Imbe K, Nagata N, Kojima Y, Yokoi C, Uemura N, Shimoyama Y, Kawamura O, Yamada M, Kusano M.
    Digestion; 2020 Jun; 101(2):174-183. PubMed ID: 30897577
    [Abstract] [Full Text] [Related]

  • 4. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, Bertani L, Furnari M, Savarino V, Blandizzi C, Marchi S.
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [Abstract] [Full Text] [Related]

  • 5. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
    Ranaldo N, Losurdo G, Iannone A, Principi M, Barone M, De Carne M, Ierardi E, Di Leo A.
    Cell Death Dis; 2017 Sep 07; 8(9):e3040. PubMed ID: 28880273
    [Abstract] [Full Text] [Related]

  • 6. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H, Kanamori A, Kano C, Hashimura H, Matsumoto K, Tsujimae M, Yoshizaki T, Momose K, Obata D, Eguchi T, Fujita M, Okada A.
    Digestion; 2017 Sep 07; 96(1):52-59. PubMed ID: 28662503
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G, Vassalle J, Marcus SN, Triadafilopoulos G.
    Dis Esophagus; 2013 Jul 07; 26(5):443-50. PubMed ID: 22862422
    [Abstract] [Full Text] [Related]

  • 10. Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring.
    Xiao Y, Liang M, Peng S, Zhang N, Chen M.
    J Gastroenterol Hepatol; 2016 Feb 07; 31(2):350-4. PubMed ID: 26202002
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
    Abe Y, Koike T, Saito M, Okata T, Nakagawa K, Hatta W, Asanuma K, Uno K, Asano N, Imatani A, Masamune A.
    Digestion; 2021 Feb 07; 102(3):480-488. PubMed ID: 32062650
    [Abstract] [Full Text] [Related]

  • 13. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M, Nakahara K, Iwakura N, Hasegawa T, Oyama M, Inoue A, Ishizu H, Satoh H, Fujiwara Y.
    Digestion; 2017 Feb 07; 95(4):281-287. PubMed ID: 28501868
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M, Cicala M, Zentilin P, Neri M, Mauro A, Efthymakis K, Petitti T, Savarino V, Penagini R.
    Aliment Pharmacol Ther; 2018 Nov 07; 48(10):1074-1081. PubMed ID: 30294924
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y, Ishibashi E, Honda S, Nakaya T, Noguchi C, Kagawa K, Murakami K.
    Medicine (Baltimore); 2020 Mar 07; 99(11):e19520. PubMed ID: 32176102
    [Abstract] [Full Text] [Related]

  • 17. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y, Liu J, Tan X, Dai Y, Xie C, Li X, Lu Q, Kou F, Jiang H, Li J.
    Dig Dis Sci; 2021 Jan 07; 66(1):19-28. PubMed ID: 32095968
    [Abstract] [Full Text] [Related]

  • 18. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.
    Becker V, Grotz S, Schlag C, Nennstiel S, Beitz A, Haller B, Schmid RM, Meining A, Bajbouj M.
    World J Gastroenterol; 2014 Apr 14; 20(14):4017-24. PubMed ID: 24744591
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease.
    Yamashita H, Okada A, Naora K, Hongoh M, Kinoshita Y.
    Dig Dis Sci; 2019 Mar 14; 64(3):823-831. PubMed ID: 30465175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.